These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

582 related items for PubMed ID: 22554238

  • 1. Intravitreal bevacizumab for extrafoveal choroidal neovascularization after ocular trauma.
    De Benedetto U, Battaglia Parodi M, Knutsson KA, Librando A, Bandello F, Lanzetta P, Iacono P.
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):550-2. PubMed ID: 22554238
    [Abstract] [Full Text] [Related]

  • 2. Intravitreal bevacizumab for nonsubfoveal choroidal neovascularization associated with angioid streaks.
    Battaglia Parodi M, Iacono P, La Spina C, Berchicci L, Scotti F, Leys A, Introini U, Bandello F.
    Am J Ophthalmol; 2014 Feb; 157(2):374-377.e2. PubMed ID: 24211865
    [Abstract] [Full Text] [Related]

  • 3. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
    Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Bandello F.
    Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
    [Abstract] [Full Text] [Related]

  • 4. Intravitreal Bevacizumab for Traumatic Choroidal Rupture.
    Kim M, Kim JH, Seo Y, Koh HJ, Lee SC.
    Optom Vis Sci; 2015 Oct; 92(10):e363-7. PubMed ID: 26367340
    [Abstract] [Full Text] [Related]

  • 5. Intravitreal bevacizumab injection in patients with choroidal neovascularization due to choroid rupture after blunt-head trauma.
    Artunay O, Rasier R, Yuzbasioglu E, Sengül A, Bahcecioglu H.
    Int Ophthalmol; 2009 Aug; 29(4):289-91. PubMed ID: 18825317
    [Abstract] [Full Text] [Related]

  • 6. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.
    Zhang H, Liu ZL, Sun P, Gu F.
    Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109
    [Abstract] [Full Text] [Related]

  • 7. Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia.
    Parodi MB, Iacono P, Papayannis A, Kontadakis S, Cascavilla ML, Zucchiatti I, Bandello F.
    Retina; 2013 Mar; 33(3):593-7. PubMed ID: 23190919
    [Abstract] [Full Text] [Related]

  • 8. Treatment of choroidal neovascularization using intravitreal bevacizumab.
    Pedersen R, Soliman W, Lund-Andersen H, Larsen M.
    Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757
    [Abstract] [Full Text] [Related]

  • 9. Intravitreal Bevacizumab for Nonsubfoveal Choroidal Neovascularization Associated With Angioid Streaks: 3-Year Follow-up Study.
    Iacono P, Battaglia Parodi M, La Spina C, Bandello F.
    Am J Ophthalmol; 2016 May; 165():174-8. PubMed ID: 27013066
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Furino C, Boscia F, Recchimurzo N, Besozzi G, Cardascia N, Sborgia L, Niro A, Sborgia C.
    Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
    [Abstract] [Full Text] [Related]

  • 12. Juxtafoveal choroidal neovascularization associated with retinitis pigmentosa treated with intravitreal bevacizumab.
    Battaglia Parodi M, De Benedetto U, Knutsson KA, Scotti F, Librando A, Bandello F, Iacono P.
    J Ocul Pharmacol Ther; 2012 Apr; 28(2):202-4. PubMed ID: 22149640
    [Abstract] [Full Text] [Related]

  • 13. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.
    Retina; 2007 Apr; 27(4):432-8. PubMed ID: 17420694
    [Abstract] [Full Text] [Related]

  • 14. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML, Malvitte L, Bidot S, Bron A, Creuzot-Garcher C.
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [Abstract] [Full Text] [Related]

  • 15. Functional and anatomic changes in bilateral choroidal neovascularization associated with vitelliform macular dystrophy after intravitreal bevacizumab.
    Cennamo G, Cesarano I, Vecchio EC, Reibaldi M, de Crecchio G.
    J Ocul Pharmacol Ther; 2012 Dec; 28(6):643-6. PubMed ID: 22742532
    [Abstract] [Full Text] [Related]

  • 16. Long-term effectiveness of intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks in pseudoxanthoma elasticum.
    Finger RP, Charbel Issa P, Schmitz-Valckenberg S, Holz FG, Scholl HN.
    Retina; 2011 Dec; 31(7):1268-78. PubMed ID: 21386758
    [Abstract] [Full Text] [Related]

  • 17. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
    Yang HS, Kim JG, Kim JT, Joe SG.
    Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
    [Abstract] [Full Text] [Related]

  • 18. An atypical case of choroidal neovascularization associated with pseudoxanthoma elasticum treated with intravitreal bevacizumab: a case report.
    Karampelas M, Soumplis V, Karagiannis D, Parikakis E, Webster AR.
    BMC Res Notes; 2013 Dec 11; 6():530. PubMed ID: 24325973
    [Abstract] [Full Text] [Related]

  • 19. Intravitreal bevacizumab for treatment of choroidal neovascularization secondary to toxoplasmic retinochoroiditis: a case series.
    Kianersi F, Naderi Beni A, Naderi Beni Z, Ghanbari H.
    Semin Ophthalmol; 2015 May 11; 30(3):181-7. PubMed ID: 24175641
    [Abstract] [Full Text] [Related]

  • 20. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
    Chan WM, Lai TY, Liu DT, Lam DS.
    Am J Ophthalmol; 2007 Jun 11; 143(6):977-983. PubMed ID: 17459318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.